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Background: Regulated intramembrane proteolysis of Epithelial cell adhesion molecule (EpCAM) results in release
of its intracellular domain (Ep-ICD) which triggers oncogenic signalling. The clinical significance of Ep-ICD in breast
cancer remains to be determined. Herein, we examined the expression of nuclear and cytoplasmic Ep-ICD, and
membranous extracellular domain of EpCAM (EpEx) in breast cancer patients, to determine its potential utility in
predicting aggressive clinical course of the disease.
Methods: In this retrospective study, 266 breast cancers and 45 normal breast tissues were immunohistochemically
analyzed to determine the expression patterns of nuclear and cytoplasmic Ep-ICD and membranous EpEx and
correlated with clinicopathological parameters and follow up. Disease-free survival was determined by Kaplan-Meier
method and multivariate Cox regression analysis.
Results: Nuclear Ep-ICD was more frequently expressed in breast cancers compared to normal tissues. Significant
association was observed between increased nuclear Ep-ICD expression and reduced disease-free survival in patients
with ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) (p < 0.001). Nuclear Ep-ICD was positive in all
the 13 DCIS and 25 IDC patients who had reduced disease-free survival, while none of the nuclear Ep-ICD negative
DCIS or IDC patients had recurrence during the follow up period. Notably, majority of IDC patients who had recurrence
had early stage tumors. Multivariate Cox regression analysis identified nuclear Ep-ICD as the most significant predictive
factor for reduced disease-free survival in IDC patients (p = 0.011, Hazard ratio = 80.18).
Conclusion: Patients with nuclear Ep-ICD positive breast cancers had poor prognosis. The high recurrence of disease
in nuclear Ep-ICD positive patients, especially those with early tumor stage suggests that nuclear Ep-ICD accumulation
holds the promise of identifying early stage patients with aggressive disease who are likely to be in need of more
rigorous post-operative surveillance and/or treatment.
Keywords: Breast cancer, Ductal carcinoma in situ, Invasive ductal carcinoma, Invasive lobular carcinoma, Invasive
mucinous carcinoma, Lobular carcinoma in situ, EpCAM, Ep-ICD and EpExBackground
Breast cancer is the most frequently diagnosed cancer in
females, with an estimated 1.38 million new cases per year
worldwide [1,2] and an estimated 226 870 new cases in the
United States in 2012 [1,2]. Globally, there are 458 000
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unless otherwise stated.common cause of cancer death in women in both the de-
veloped and developing countries [1]. In early stage breast
carcinoma patients, the presence of metastases to axillary
lymph nodes is the most important predictor of survival
[3]. Patients with node-positive tumors have up to an 8-
fold increase in mortality than node-negative patients [4].
The heterogenic nature of breast carcinomas and diverse
patterns of growth and invasiveness emphasize the need
for prognostic and predictive biological markers for aggres-
sive tumors. This is particularly important in light of the
fact that many detected carcinomas may be non-aggressive
[5]. Furthermore, population breast cancer screening withral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mors and has the potential to lower mortality, but it is also
associated with the risk of overtreatment of less aggressive
subtypes resulting in unnecessary treatment of tumors that
would not have adversely affected the patient [6]. There-
fore, it is important to identify more aggressive lesions at
an earlier stage for rigorous treatment.
Current clinical therapies for breast cancer include sur-
gery, radiotherapy and drug therapies targeting oncogenic
processes that are offered on an individual patient basis.
The prediction of treatment response and propensity for
metastasis remain challenging, and reflect an incomplete
understanding of the biology of different breast cancer sub-
types. A large number of patients are over-treated to
achieve improved overall survival in early breast cancer.
Defining individual risk of disease recurrence or sensitivity
to treatment will considerably reduce over-treatment and
enable personalised treatment so that patients only receive
the optimal treatment required to achieve the cure. Gen-
omic tests (Mammaprint, Oncotype Dx, PAM50) and im-
munohistochemical tests (IHC 4) have been developed for
prediction of disease prognosis and response to chemother-
apy; prospective validation of these is still awaited [7]. Nu-
clear magnetic resonance (NMR) and mass spectrometry
(MS) based serum metabolite profiling has been shown to
accurately identify 80% of breast cancer patients whose tu-
mors failed to respond to chemotherapy suggesting prom-
ise for personalised treatment protocols [8]. Recently, a
five-gene Integrated Cytokine score (ICS) has been pro-
posed for predicting metastatic outcome from primary hor-
mone receptor negative and/or triple negative breast
tumors independent of nodal status, adjuvant chemother-
apy use, and triple negative molecular subtype [9].
Epithelial Cell Adhesion Molecule (EpCAM) is a trans-
membrane glycoprotein expressed in several human
epithelial tissues and frequently overexpressed in cancer,
progenitor, and stem cells [10]. EpCAM consists of an
extracellular epidermal growth factor-like (EGF) domain
(EpEx), thyroglobulin domain, transmembrane region, and
a short intracellular domain (Ep-ICD) [11,12]. In normal
cells, EpCAM appears to be sequestered in tight junctions
and is therefore less accessible to antibodies, whereas in
cancer cells it is widely distributed on the cell surface and
has therefore been explored as a surface-binding site for
therapeutic antibodies [13-16]. EpCAM has been widely
investigated for its diagnostic and therapeutic potential as
it is expressed in the majority of human epithelial cancers,
including breast, colon, gastric, head and neck, prostate,
pancreas, ovarian and lung cancer [17-20]. Increased
EpCAM expression has been found to be a poor prognos-
tic marker in breast and gall bladder carcinomas [21,22].
In contrast EpCAM expression in colorectal and gastric
cancer is associated with favorable prognosis [23,24].
This paradoxical association of EpCAM expression withprognosis in different cancers is supported by functional
studies of EpCAM biology using in vitro and in vivo can-
cer models as well. Taken together these studies suggest
that the impact of EpCAM expression in human cancers
is likely to be context dependent [25]. EpCAM expression
based assay has been FDA approved and widely used to
detect circulating tumor cells in breast cancer [26]. Due to
its high-expression and association with poor prognosis,
EpCAM has been widely explored as a potential target
for antibody-based immunotherapies. EpCAM-targeted
molecular therapies are being intensely pursued for
several cancers including breast, ovarian, gastric and
lung cancer [27]. EpCAM expression has been used to
predict response to anti-EpCAM antibodies in breast
cancer patients [27-29]. Surprisingly clinical trials of
anti-EpCAM antibodies targeting the EpEx domain have
shown limited efficacy [29,30]. These paradoxical outcomes
are potentially explainable by the recently described regu-
lated intramembrane proteolysis of EpCAM, resulting in
oncogenic signaling by its intracellular domain, Ep-ICD
[31]. Previously, we reported accumulation of Ep-ICD is
frequently detected in ten epithelial cancers, including
breast and prostate [32,33]. In thyroid carcinomas nuclear
Ep-ICD accumulation predicted poor prognosis and was
elevated in patients with anaplastic tumors [33].
The aim of this study is to evaluate the prognostic utility
of Ep-ICD by characterizing the subcellular expression
of Ep-ICD and EpEx in breast carcinomas using immu-
nohistochemistry and correlating with clinicopathological
parameters and the follow up of patients to investigate its
potential to predict aggressive tumors that may aid in the
management of breast cancer patients.
Methods
Patient and tumor specimens
This retrospective study of biomarkers using the breast
cancer patients’ tissue blocks stored in the archives of
the Department of Pathology and Laboratory Medicine
and their anonymized clinical data was approved by the
Mount Sinai Hospital Research Ethics Board, Toronto,
Canada. The patients whose records were used for this
study granted informed consent for their tissue samples
to be archived and used for research purposes. In view
of the retrospective study, the need for consent for use
of anonymized clinical data was waived-off by the
Institutional Research Ethics Board. The patient cohort
consisted of 266 breast cancer patients treated at
Mount Sinai Hospital, a tertiary care hospital in Toronto,
Ontario, Canada between 2000 and 2007. The series
consisted of patients who had mastectomy or lumpectomy.
Inclusion criteria: Breast cancer tissue samples of patients
that had up to 60 months follow-up and availability of
clinical, pathological and treatment data in the clinical
database.
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considered for this study if patients follow up data were
not available in the clinical database.
Normal breast tissues were chosen from breast reduc-
tion surgeries, normal tissue with adjacent benign lesions,
and prophylactic mastectomies. Normal breast tissues
from adjacent cancers were not included in this study.
Our patient cohort consisted of individuals with invasive
ductal carcinoma (IDC) (n = 180), invasive lobular carcin-
oma (ILC) (n = 15), invasive mucinous carcinoma (IMC)
(n = 9), ductal carcinoma in situ (DCIS) (n = 61), and lobu-
lar carcinoma in situ (LCIS) (n = 1) and 45 individuals
with normal breast tissues. The diagnosis was based on
histopathological analysis of the tissue specimens. The
follow-up time for all patients including IDC cases in the
study was 60 months. The clinicopathological parameters
recorded included age at surgery, tumor histotype, tumor
size, AJCC pTNM stage, nodal status, tumor grade,
recurrence of disease, ER/PR status, hormonal treatment,
radiation therapy, and/or chemotherapy. Her2 status data
were not available for all breast cancer patients in the
clinical database and thus could not be included in this
study. Formalin-fixed paraffin-embedded tissue blocks
of all patients included in this study were retrieved
from the Mount Sinai Hospital (MSH) tumor bank,
reviewed by the pathologists and used for cutting tissue
sections for immunohistochemical staining with Ep-ICD
and EpEx specific antibodies as described below.
Immunohistochemistry (IHC)
Formalin-fixed paraffin embedded sections (4 μm thick-
ness) of breast carcinomas were used for Ep-ICD and
EpEx immunostaining as described [33]. In brief, for
EpEx following deparaffinization and rehydration, antigen
retrieval was carried out using a microwave oven in
0.01 M citrate buffer, pH 3.0 and endogenous peroxidase
activity was blocked by incubating the tissue sections in
hydrogen peroxide (0.3%, v/v) for 20 min. For Ep-ICD, the
tissue sections were de-paraffinized by baking at 62°C for
1 hour in vertical orientation, treated with xylene and
graded alcohol series, and the non-specific binding was
blocked with normal horse or goat serum. Rabbit anti-
human Ep-ICD monoclonal antibody from Epitomics Inc.
(Burlingame, CA) was used in this study. The α-Ep-ICD
antibody 1144 recognizes the cytoplasmic domain of
human EpCAM and has been used in our previous
study of Ep-ICD expression in thyroid carcinoma and
other epithelial cancers [33]. Anti-EpCAM monoclonal
antibody EpEx (MOC-31, AbD Serotec, Oxford, UK)
recognizes an extracellular component (EGF1 domain- aa
27–59) in the amino-terminal region [34]. The sections
were incubated with either α-Ep-ICD rabbit monoclonal
antibody 1144 (dilution 1:1500) or mouse monoclonal anti-
body MOC-31 (dilution 1:200) for 60 minutes, followed bybiotinylated secondary antibody (goat anti-rabbit or goat
anti-mouse) for 20 minutes. The sections were finally
incubated with VECTASTAIN Elite ABC Reagent (Vector
Laboratories, Burlington, ON, Canada) and diaminobenzi-
dine was used as the chromogen. Tissue sections were
then counterstained with hematoxylin. Negative controls
comprised of breast tissue sections incubated with isotype
specific IgG in place of the primary antibody, and positive
controls (colon cancer tissue sections known to express
Ep-ICD) were included with each batch of staining for
both Ep-ICD and EpEx.
Evaluation of IHC and scoring
Immunopositive staining was evaluated in five areas of
the tissue sections representing the highest tumor grade
(Nottingham system) by two researchers blinded to the
final outcome and the average of these five scores was
calculated as described by us [33]. Sections were scored
on the basis of both the percentage of immunopositive
cells and intensity of staining. For percentage positivity,
cells were assigned scores based on the following
scheme: 0, < 10% cells; 1, 10–30% cells; 2, 31–50% cells; 3,
51–70% cells; and 4, >70% cells showing immunoreactiv-
ity. Sections were also scored semi-quantitatively on the
basis of intensity of staining as follows: 0, none; 1, mild; 2,
moderate; and 3, intense. A final score (ranging from 0
to 7) for each tissue section was obtained by adding the
scores of percentage positivity and intensity for each of
the breast cancer tissue sections. The average total
score from the five areas was used for further statistical
analysis. Each tissue section was scored for cytoplasmic
and nuclear Ep-ICD as well as for membrane EpEx fol-
lowing this scoring scheme.
Statistical analysis
The immunohistochemical data were subjected to statis-
tical analysis with SPSS 21.0 software (SPSS, Chicago, IL)
and GraphPad Prism 6.02 software (GraphPad Software,
La Jolla, CA) as described previously [35]. A two-tailed
p-value was used in all analyses and a p value < 0.05 was
considered statistically significant. Chi-square analysis was
used to determine the relationship between Ep-ICD and
EpEx expression and the clinicopathological parameters.
Disease-free survival was analyzed by the Kaplan-Meier
method and multivariate Cox regression. Hazard ratios
(HR), 95% confidence intervals (95% CI), and p values
were estimated using the log-rank test. Disease-free
survival or clinical recurrence, distal metastases, and/or
death were considered to be the endpoint of the study.
The cut-offs for statistical analysis were based upon the
optimal sensitivity and specificity obtained from the
Receiver operating curves as described [32]. For nuclear
Ep-ICD, an IHC score cut-off value of ≥ 2 was defined
as immunopositive for all tissues analyzed for statistical
Table 1 Clinicopathological characteristics of breast
cancer patients in the study cohort
Breast cancer (n = 266) IDC (n = 180)
Surgical treatment
Lumpectomy 168 (63.1%) 113 (62.8%)
Mastectomy 84 (31.6%) 59 (32.8%)
Unknown 14 (5.3%) 8 (4.4%)
Age at diagnosis (years)
Median (Range - 30.6–89.8) 59.2 59.2
< 59 126 (47.4%) 88 (48.9%)
≥ 59 140 (52.6) 92 (51.1%)
Adjuvant treatment
Hormonal treatment
Tamoxifen 131 (49.2%) 94 (52.2%)
Aromatase Inhibitor 13 (4.9%) 8 (4.4%)
Chemotherapy 73 (2.7%) 66 (24.8%)
Radiotherapy 149 (56.0%) 101 (56.1%)
Therapy details not available 6 (2.2%) 6 (3.3%)
Tumor size (cm)
Mean ± SD 1.85 ± 1.525 1.82 ± 1.466
Minimum 0.1 0.1
Maximum 9 9
≤2 cm 198 81
>2 cm 57 96
Unknown 11 3
AJCC pTNM stage (n, %)
0 (DCIS + LCIS) 62 (23.3%) -
I 94 (35.3%) 113(62.8%)
II 87 (32.7%) 58 (32.2%)
III 6 (2.3%) 5 (2.8%)
IV 17 (6.4%) 4 (2.2%)
Estrogen receptor (ER)
Negative 35 (13.1%) 33 (18.3%)
Positive 161 (60.6%) 136 (75.6%)
Unknown 70 (26.3%) 11 (6.1%)
Progesterone receptor (PR)
Negative 71(26.7%) 64 (35.6%)
Positive 123 (46.2%) 103 (57.2%)
Unknown 72 (27.1%) 13 (7.2%)
Grade
I 56 (21.1%) 42 (23.3%)
II 106 (39.8%) 66 (36.7%)
III 85 (32.0%) 65 (36.1%)
Unknown 19 (7.1%) 7 (3.9%)
Nodal status
Negative 204 (76.7%) 123 (68.3%)
Positive 62 (23.3%) 57 (31.7%)
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positive with an IHC cut-off value of ≥ 4. Membranous
EpEx positivity was defined as membrane EpEx IHC
score of ≥ 3.
Results
The clinicopathological parameters and treatment details of
all the 266 breast cancer patients and 45 normal controls
are summarized in Table 1. The median age of patients was
59.9 years (range 30.6–89.8 years). AJCC pTNM Stage I
(35.3%) and II (32.7%) comprised a large proportion of
tumors in this cohort. Tumor grades distribution was
Grade I - 21.1%; II - 39.8%, and III - 32.0%. Among the
IDC cases, majority were also AJCC pTNM Stage I
(62.8%) and II (32.2%). The IDC cases comprised of Grade
I - 23.3%; Grade II - 36.7%; and Grade III - 36.1% tumors.
Expression of Ep-ICD and EpEx in breast cancer tissues
To determine the pattern of expression of Ep-ICD and
EpEx in breast cancer, tissues of DCIS, IDC, ILC, and
IMC were analyzed by IHC and compared to normal
breast tissues. A summary of the percentage positivity for
nuclear Ep-ICD, cytoplasmic Ep-ICD, and membranous
EpEx and loss of membranous EpEx is provided in Table 2.
Representative photomicrographs of Ep-ICD and EpEx
expression in breast cancer subtypes are shown in
Figures 1 and 2. Of 266 breast carcinomas examined,
121 (46%) were positive for nuclear Ep-ICD and 185
(70%) were positive for membranous EpEx, while 81
cases showed loss of membranous EpEx expression.
This compares to 11 of 45 (24%) normal breast tissues
immunopositive for nuclear Ep-ICD and 19 of 45 (42%)
positive for membranous EpEx. Notably, 12 of 15 ILCs
showed loss of membranous EpEx, compared to 14 of
61 (23%) DCIS, 52 of 180 (29%) IDC and 3 of 9 IMC.
Cytoplasmic Ep-ICD was frequently present in all histo-
logic subtypes examined and normal tissues. Nuclear
Ep-ICD was more frequently positive in breast carcinomas
(121 of 266, 46%) compared to normal tissues (11 of
45, 24%). Evaluation of the individual subtypes showed
nuclear Ep-ICD accumulation was frequently detected
in ILC (10 of 15 tumors), 30 of 61 DCIS, 75 of 180
IDC, and 5 of 9 IMC cases.
Relationship of Ep-ICD with clinicopathological
characteristics of IDC patients
Nuclear and cytoplasmic Ep-ICD expression in IDC
patients’ and their association with the clinicopathological
characteristics are given in Table 3. Notably, nuclear Ep-
ICD accumulation was significantly associated with and
observed in all IDC patients with clinical recurrences [25
of 25 patients, p < 0.001, Odds ratio (OR) = 1.50, 95%
confidence interval (CI) = 1.28–1.76]. Nuclear Ep-ICD
overexpression was significantly associated with low or
Table 2 Expression of nuclear and cytoplasmic Ep-ICD and membranous EpEx in normal tissues and breast cancer
histotypes










Normal 45 11 (24% ) 39 (87%) 19 (42%) 26 (58%)
Breast cancer 266 121 (46%) 215 (81%) 185 (70%) 81 (30%)
Histotypes*
DCIS 61 (22.9%) 30 (49%) 48 (79%) 47 (77%) 14 (23%)
IDC 180 (67.6%) 75 (42%) 145 (81%) 128 (71%) 52 (29%)
ILC 15 10 12 3 12
IMC 9 5 9 6 3
For nuclear Ep-ICD a cut off of ≥ 2 was used to determine positivity. For cytoplasmic Ep-ICD the cut off was ≥ 4. For membranous EpEx a cut off of ≥ 3 was
considered positive.
*1 LCIS was also included in the study (data not shown in table).
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tients, 49%; p = 0.018, OR = 0.46, 95% CI = 0.24–0.89) and
no lymph node metastases at surgery (58 of 123 patients,
47%; p = 0.028, OR = 0.48, 95% CI = 0.24–0.98). No associ-
ation was observed between nuclear or cytoplasmic Ep-
ICD and ER/PR status, AJCC pTNM stage, T-stage, tumor
size, or patient’s age at diagnosis (Table 3). Membranous
EpEx or loss of membranous EpEx did not show significant
correlation with any of the clinico-pathological parameters
in this cohort of breast cancer patients (data not shown).Figure 1 Immunohistochemical analysis of Ep-ICD expression in breast ca
cytoplasmic Ep-ICD expression in normal breast tissues. Nuclear and cytoplasmi
(VI) negative control breast cancer tissue incubated with isotype specific IgG sh
and C depict nuclear, and cytoplasmic staining respectively. (original magnificatIt is important to note that recurrence, distal metastases,
and/or death was observed in 42 of 121 (34.7%) breast car-
cinoma patients. Subgroup analysis of IDC patients that
were positive for nuclear Ep-ICD showed recurrence in 25
of 75 (33.3%) patients. Importantly, in the entire cohort of
breast carcinoma patients, only patients who were positive
for nuclear Ep-ICD accumulation had disease recurrence.
Notably, evaluation of all patients who had recurrence
showed that of these 42 patients, 37 (88.1%) had early
stage tumors (AJCC pTNM Stage I or II), while 5 (11.9%)ncer. Representative photomicrographs demonstrating: (I) predominantly
c accumulation of Ep-ICD in: (II) DCIS; (III) IDC; (IV) ILC; (V) IMC; and
owing no detectable immunostaining for Ep-ICD. The arrows labelled N
ion × 400).
Figure 2 Immunohistochemical analysis of EpEx expression in breast cancer. Expression of EpEx in (I) normal breast tissues; (II) DCIS; (III) IDC;
(IV) ILC; (V) IMC; (VI) negative control breast cancer tissue incubated with isotype specific IgG showing no detectable immunostaining for EpEX.
Membranous EpEx expression was more frequently observed in breast carcinomas compared to normal tissues, except ILC (original magnification ×
400). The arrows labelled M depict membrane staining.
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who had adverse clinical events, 21 of 25 (84%) had early
stage tumors (AJCC pTNM Stage I and II), while 4 of 25
(16%) were AJCC pTNM Stage III and IV cases.
Prognostic value of Ep-ICD expression for disease-free
survival
We evaluated the association between nuclear Ep-ICD
accumulation, clinicopathological parameters and disease-
free survival (Table 4). Significant association was observed
between nuclear Ep-ICD expression in DCIS patients and
disease-free survival (p < 0.001; Figure 3A). In contrast, all
the 31 patients who did not show nuclear Ep-ICD positivity
were alive and free of disease even after 5-years post-
treatment. IDC patients also showed significant association
between nuclear Ep-ICD expression and reduced disease-
free survival (p < 0.001; Figure 3B). In contrast, all the 105
IDC patients with no nuclear Ep-ICD positivity were alive
and free of disease as of 5-years following surgery.
Among the IDC cases, Cox multivariate regression ana-
lysis showed nuclear Ep-ICD to be the most important
prognostic marker for reduced disease-free survival
(p = 0.011, HR = 80.18, 95% C.I. = 2.73–2352.2). Fifty of
75 nuclear Ep-ICD positive IDC patients did not have
recurrence during this follow up period.Discussion
Ever since the regulated intramembrane proteolysis of
EpCAM was described as a novel mechanism of triggering
oncogenic signalling by Maetzel et al. [31], investigation
of Ep-ICD expression in human epithelial cancers for
determination of its clinical relevance is in hot pursuit. Our
earlier preliminary study reported frequent nuclear and
cytoplasmic Ep-ICD expression in ten different epithelial
cancers, including a small number of breast cancers
[33]. This first report did not examine the correlation
of nuclear Ep-ICD expression with clinical parameters
or its prognostic utility in these cancers. The current
study assessed the potential suitability of Ep-ICD as a
marker in predicting clinical course and aggressiveness
of breast cancer. Although expression of the full length
EpCAM protein has been widely investigated in human
malignancies, the expression and subcellular localization
of its intracellular domain Ep-ICD has not been well
characterized in clinical specimens. Our study demon-
strated differences in expression of Ep-ICD and EpEx
between normal and malignant breast tissues and their
relationship with disease prognosis, providing valuable
information as to their suitability as potential biological
markers. Given the interest in the therapeutic potential
of EpCAM targeted therapies in cancer management
Table 3 Nuclear and cytoplasmic Ep-ICD expression in invasive ductal carcinoma (IDC) and correlation with
clinicopathological parameters
Clinicopathological parameters Total cases (n = 180) Ep-ICD
Nuclear
p-value Odd’s ratio (95% C.I.) Ep-ICD
Cytoplasm
p-value Odd’s ratio (95% C.I.)
N (%) n (%)
IDC cases 75 42 - - 145 81 - -
Age
< 59 years 88 39 44.3 74 84.1
≥ 59 years 92 36 39.1 0.480 0.80 (0.45–1.45) 71 77.2 0.241 0.64(0.30–1.36)
Tumor Sizea
≤2 cm 81 35 43.2 69 85.2
> 2 cm 96 37 38.5 0.529 0.82 (0.45–1.50) 73 76.0 0.128 0.55(0.25–1.20)
T-stage
T1 + T2 171 71 41.5 138 80.7
T3 + T4 9 4 44.4 0.862 1.13 (0.30–4.34) 7 77.8 0.829 0.84(0.17–4.22)
Nodal Status
Nx+0 123 58 47.2 99 80.5
N1–3 57 17 29.8 0.028 0.48 (0.24–0.98) 46 80.7 0.973 1.02(0.45–2.24)
Stage
I + II 159 68 42.8 130 81.8
III + IV 21 7 33.3 0.410 0.67 (0.26–1.74) 15 71.4 0.261 0.56(0.20–1.56)
Gradeb
I + II 108 53 49.1 90 83.3
III 65 20 30.8 0.018 0.46 (0.24–0.89) 48 73.8 0.132 0.57(0.27–1.20)
Clinical Recurrence
No 155 50 32.3 121 78.1
Yes 25 25 100 <0.001 1.50 (1.28–1.76) 24 96.0 0.035 6.75(0.88–51.67)
ER/ PR statusc
ER+ 136 62 45.6 112 82.4
ER− 33 12 36.4 0.338 1.47 (0.67–3.22) 25 75.8 0.386 1.49(0.60–3.71)
PR+ 103 49 47.6 88 85.4
PR− 64 25 39.1 0.282 1.42 (0.75–2.67) 48 75.0 0.092 1.96(0.89–4.30)
ER+PR+ 103 49 47.6 88 85.4
ER−PR− 33 12 36.4 0.260 1.59(0.70–3.56) 25 75.8 0.197 1.96(0.89–4.30)
aTumor Size was available for 177 IDCs; bTumor Grades were available for 173 IDCs; cER and PR status was available for 169 and 167 IDCs only in our clinical
databases. Membranous EpEx expression or loss of Membranous EpEx did not show significant correlation with any clinical or pathological parameters, hence the
data are not shown in this Table. The p-value in boldface are statically significant.
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pattern of Ep-ICD in breast cancer, our study helps to shed
light on this widely-studied, yet not fully understood
protein. Furthermore, our study is the first in-depth
characterization of Ep-ICD expression in IDC of the breast.
Importantly, increased detection of nuclear Ep-ICD in
breast carcinomas compared to normal tissues warrants
exploration of its potential role in tumorigenesis. The
increased regulated intramembrane proteolysis of EpCAM
resulting in release of its cytoplasmic domain, Ep-ICD,
and its subsequent translocation to the nucleus has been
demonstrated to trigger oncogenic signalling in coloncarcinoma [31]. In an earlier study, we reported that nu-
clear Ep-ICD accumulation predicted poor prognosis in
thyroid carcinomas and was elevated in patients with ana-
plastic tumors [33]. Taken together with our present study,
these reports underscore the biological significance of in-
creased nuclear Ep-ICD in cancer. The discovery of the
tumor-suppressive properties of EpCAM in some cancers
has surprised many researchers, given its association with
poor prognosis in many other cancers. Some studies have
suggested the tumor microenvironment may be an import-
ant factor in dictating whether EpCAM will promote or in-
hibit tumor progression, particularly given its ability to
Table 4 Kaplan-Meier survival analysis and multivariate Cox regression analysis for breast cancer patients







Nuclear Ep-ICD+ <0.001 0.011 80.183 2.733–2352.2
Cytoplasmic Ep-ICD+ 0.048 0.496 —— ——
Age 0.796 0.787 —— ——
Tumor size 0.556 0.516 —— ——
T-stage 0.237 0.366 —— ——
Nodal status 0.814 0.398 —— ——
Clinical Stage 0.129 0.809 —— ——
Grade 0.329 0.062 —— ——
ER status 0.384 0.678 —— ——
PR status 0.984 0.499 —— ——
The p-value in boldface are statically significant.
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[10]. Furthermore, regulated intramembrane proteolysis of
EpCAM and the associated oncogenic signalling by Ep-
ICD may shed light on some of these observations as add-
itional protein-protein interactions are uncovered [13,36].
Recently, the endoplasmic reticulum aminopeptidase 2
(ERAP2), a proteolytic enzyme set in the endoplasmic
reticulum (ER) has been shown to co-localize with EpCAM
in the cytoplasm/ER where it plays a central role in the
trimming of peptides for presentation by MHC class I mol-
ecules. This association between EpCAM and ERAP2Figure 3 Kaplan-Meier curves for disease-free survival (DFS) stratified
accumulation of Ep-ICD was associated with significantly reduced DFS in D
accumulation, 13 recurrences of DCIS were observed. In contrast, no recurr
immunopositivity and these patients were recurrence free for 60 months. B
reduced DFS in IDC patients (p < 0.001). In 75 patients positive for nuclear
was observed in 105 patients who did not show nuclear Ep-ICD immunopsuggests a new mechanism of EpCAM processing and
regulation of antigen presentation in breast cancer [37].
Our study revealed several important findings with
potentially significant implications for the use of Ep-ICD as
a biomarker. We observed high occurrence of recurrence,
distal metastases, or death among IDC patients who were
positive for nuclear Ep-ICD accumulation. In contrast, no
recurrence distal metastases, or death were observed in
nuclear Ep-ICD negative patients during the follow up
period. Importantly, a great majority of patients with
recurrence (37 of 42, 88.1%) had early stage breastby nuclear Ep-ICD expression in DCIS and in IDC. A. Nuclear
CIS patients (p < 0.001). In 30 patients positive for nuclear Ep-ICD
ence was observed in 31 patients who did not show nuclear Ep-ICD
. Nuclear accumulation of Ep-ICD was associated with significantly
Ep-ICD accumulation, 25 events were observed. In contrast, no event
ositivity and patients were alive for 60 months.
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normally be considered lower-risk for future recurrence.
Moreover, the fact that only nuclear Ep-ICD positive
patients had recurrence and that no nuclear Ep-ICD
negative patient suffered the same suggests a potential
clinical application for this biomarker. These observations
support the notion that nuclear Ep-ICD accumulation
even in early stage breast tumors holds promise for
predicting aggressive disease.
Indeed, the presence of nuclear Ep-ICD, irrespective of
tumor stage or any other clinical variable predicted a
high risk of disease recurrence. Multivariate Cox regression
analyses identified nuclear Ep-ICD accumulation as the
most significant factor for prediction of recurrence in
IDC patients. These findings, of course, require further
clinical validation in larger number of patients followed
prospectively, but are nonetheless encouraging because
it may provide a path to identify patients who may
require more aggressive monitoring and/or treatment,
particularly in patients early stage tumors who show
nuclear Ep-ICD accumulation.
The in vitro studies on functional role of EpCAM in
breast cancer cell lines demonstrated that transfection of
EpCAM resulted in increased nuclear accumulation of
β-catenin in MDA-MB-231EpCAM and upregulated Wnt
reporter assay activity in Hs578TEpCAM cells suggesting
activation of Wnt pathway [38]. Moreover, the inter-
action between membranous EpEx and the extracellular
environment and nuclear Ep-ICD and intracellular
signalling continues to reveal interesting associations.
Martowicz et al. [39] and others recently reported that
cancer cells of an epithelial but not mesenchymal pheno-
type require EpCAM as an invasion-promoting factor
[40]. It is possible that nuclear Ep-ICD accumulation is an
early indicator of tumor progression, as evidenced by its
correlation with lower grade, but also, disease recurrence.
Furthermore, the expression of nuclear Ep-ICD and
membranous EpEx may have not only prognostic but
also therapeutic implications to stratify patients who
are likely to respond to EpCAM based immunotherapies.
In this context, a recent study in 1365 breast cancers
reported EpCAM expression varies significantly and is
differentially associated with prognosis in the luminal B
HER2 positive, basal like, and HER2 intrinsic subtypes
of breast cancer [17-20]. However, a limitation of this
study is the expression of Ep-ICD has not been analysed
and only EpCAM expression was correlated with disease
outcome. The prevalence of the full length EpCAM and
Ep-ICD in a variety of human cancers has been recently
reported using tissue microarrays suggesting loss of
membranous EpEx is a common event in human epithelial
cancers and the ratio of EpEx and Ep-ICD is dependent
on the tumor [41]. However, this study does not address
the clinical relevance of relative expression of EpEx andEp-ICD in these cancers. Future studies evaluating the
prognostic and predictive role of these variants in human
cancers, especially in patients treated with Ep-CAM
specific antibodies are warranted.
One limitation of our study is that while all the 25
IDC patients that had recurrence were nuclear Ep-ICD
positive suggesting nuclear Ep-ICD positivity is a risk
factor for aggressive disease in these patients, there were
50 of 75 nuclear Ep-ICD positive IDC patients who did
not experience any recurrence during this follow up
period. Hence there is a need to identify other protective
factors in these patients that prevent the recurrence of
disease. Another limitation is the very small number of
ILC and IMC cases analyzed in this study. Future studies
will be directed to search for additional factors which
promote or protect against recurrence in this subgroup
of nuclear Ep-ICD positive patients. Nevertheless, our
findings are important in stratifying aggressive early stage
breast cancer patients who will need rigorous follow-up
for more effective disease management. At the same
time the absence of nuclear Ep-ICD in early stage breast
cancer patients also has the potential to help avoid over-
treatment, sparing these patients the harmful side effects
of aggressive therapies and reducing health care costs
upon validation in future studies.
Conclusions
In conclusion, nuclear Ep-ICD was detected in DCIS
and IDC and found to be associated with recurrence in
these patients. The recurrence of disease only in patients
with nuclear Ep-ICD positive early stage tumors suggests
that nuclear Ep-ICD accumulation holds the promise of
identifying patients in need of more aggressive post-
operative surveillance and/or treatment. Future studies
investigating other factors that protect against recurrence
in the subgroup of nuclear Ep-ICD positive patients are
warranted to evaluate their prognostic significance. Clinical
studies of Ep-ICD vs. membranous EpEx expression based
selection of IDC patients who are likely to benefit from
treatment with EpCAM-specific antibodies will unequivo-
cally establish their utility for improving the outcome of
EpCAM based molecular therapies.
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